The Right Research Mix

Digital VisionIn April 2003, the UK's Medical Research Council established a task force to assess possible future research models for the council's National Institute of Medical Research. "We've been looking ... for any hard data that helps us look at the relative merits of different models," says MRC task force secretary David Smith, "and we're not finding it." While the council gathered lots of anecdotal material, Smith continues, "I don't think it obviously leads to any clear conclusion.No wo

Written byStuart Blackman
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Digital Vision

In April 2003, the UK's Medical Research Council established a task force to assess possible future research models for the council's National Institute of Medical Research. "We've been looking ... for any hard data that helps us look at the relative merits of different models," says MRC task force secretary David Smith, "and we're not finding it." While the council gathered lots of anecdotal material, Smith continues, "I don't think it obviously leads to any clear conclusion.

No wonder. Judging the merits of one type research model over another – and hence the research's scientific impact – is no small feat, even though such data might be desirable to help form important decisions regarding the distribution of limited resources.

The judging is tough because common denominators are scarce. Different types of models abound, including: government-funded facilities, such as the National Institutes of Health and Max-Planck-Gesellschaft; research universities, including ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies